Africa In The News
SEE OTHER BRANDS

The top news stories from Africa

Africa In The News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa In The News.

Press releases published on July 31, 2025

WestKam Gold Corp. Mobilizes Crews for Prospecting and Soil Sampling on Will Property, Mt. Williams, B.C.

WestKam Gold Corp. Mobilizes Crews for Prospecting and Soil Sampling on Will Property, Mt. Williams, B.C.

Vancouver, B.C., July 31, 2025 (GLOBE NEWSWIRE) -- WestKam Gold Corp. (the “Company” or “WestKam”) is pleased to announce that field crews are being mobilized to commence a prospecting and soil sampling program on the Company’s 100%-owned Will Project, …

ADR Ratio Change Effective

ADR Ratio Change Effective

July 31, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Effective ADSs Outstanding Post Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative …

Koryx Copper Announces Closing of $25 Million Financing

Koryx Copper Announces Closing of $25 Million Financing

Not for distribution to United States newswire services or for dissemination in the United States VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- Koryx Copper Inc. (the “Company”) (TSX-V: KRY) is pleased to announce that it has closed (i) …

Critical Metals Corp Announces the Creation of an Advisory Board

Critical Metals Corp Announces the Creation of an Advisory Board

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals mining company, today announced that it has formed an Advisory Board, which will advise Critical Metals …

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering

OCALA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”), today announced the closing of its previously announced public offering of an aggregate of 2,000,000 shares of its common stock (or pre-funded warrants …

GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) 

GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) 

Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no …

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC), to address significant unmet medical needs Inflammatory Bowel Disease is a large and growing …

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) (“Supernus”) today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. (Nasdaq: SAGE) (“Sage”). “Sage …

Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025

ASHBURN, Va., July 31, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to release its …

Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial

Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial

SARASOTA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological conditions, today announced the selection of Southern Star Research as its …

June 2025 Quarterly Activities Report

June 2025 Quarterly Activities Report

QUEBEC CITY, July 31, 2025 (GLOBE NEWSWIRE) -- West African gold producer and developer Robex Resources Inc (“Robex” or the “Company”) (TSX-V: RBX | ASX: RXR | OTC: RSRBF | Börse Frankfurt: RB4) is pleased to report on its June 2025 Quarter Activities. …

Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025

Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025

BASKING RIDGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other …

Nautilus Biotechnology Reports Second Quarter 2025 Financial Results

Nautilus Biotechnology Reports Second Quarter 2025 Financial Results

SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2025. “In Q2, …

Discovery Announces Senior Management Appointment

Discovery Announces Senior Management Appointment

TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) today announced the appointment of Alison White to the position of Chief Financial Officer (“CFO”). The appointment is effective …

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors Recent Leadership Appointments Bring Deep Experience in Oncology Drug Development, Clinical …

Effective Date of Consolidation of Shares

Effective Date of Consolidation of Shares

Vancouver, British Columbia , July 31, 2025 (GLOBE NEWSWIRE) -- First American Uranium Inc. (CSE: URM) (FSE: IOR) (OTCPK: FAUMF) (the “Company”) announces, further to its news release of July 21, 2025 and effective August 6, 2025, the Company will …

InflaRx to Report Second Quarter 2025 Results on  August 7, 2025

InflaRx to Report Second Quarter 2025 Results on August 7, 2025

JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2025 …

Osisko Development Announces US$195 Million Financing

Osisko Development Announces US$195 Million Financing

Not for distribution to U.S. news wire services or dissemination in the United States. MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Osisko Development Corp. (NYSE: ODV, TSXV: ODV) ("Osisko Development" or the "Company") announces today that it has entered …

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGN Announced capped royalty purchase agreement with Sobi under which Apellis receives up to $300 million for 90% of ex-U.S. …

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions